Inpharmatica Ltd, the selective drug discovery company, announced that it has entered into an agreement with pharmaceutical company, GlaxoSmithKline (GSK) to access its ADME (absorption, distribution, metabolism, and excretion) technologies.
Under the agreement, Inpharmatica will apply its proprietary in silico ADME technology to an undisclosed number of GSK's drug discovery programmes in the UK and Europe.
Inpharmatica has pioneered the development of a portfolio of computational tools to aid rapid, effective and balanced decision-making in Drug Discovery. Inpharmatica's in silico ADME platform addresses a major bottleneck in drug discovery and enhances productivity by providing a unique framework in which large collections of molecules or chemistry ideas can be ranked and prioritised for progression based upon their likelihood of success against Project-defined criteria. This is the fourth ADME deal to be announced by Inpharmatica in the past six months, providing further validation of the Company's expertise and industry-leading technology in this important area in Drug Discovery.
Commenting on the announcement, Dr Mike Tarbit, senior VP of Pre-clinical R & D, at Inpharmatica, said, "We are delighted with the ongoing success of our ADME business and the calibre of partners we are attracting. Inpharmatica is committed to developing and applying advanced technologies that improve both the efficiency of the Drug Discovery process and the quality of chemical leads and drug candidates produced. This agreement clearly demonstrates recognition of Inpharmatica's approach and we are delighted that GSK has chosen to use our ADME technologies and expertise."